← Russell 3000 cross-section

CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Financials

Scale

Market cap
$2.2bn
Revenue TTM
$2.5bn
Net income TTM
$-18m
Free cash flow
$74m
Composite score
31.6
Sector rank
#1586

Valuation

P / E
EV / EBITDA
EV / sales
0.9
FCF yield
3.38%
Earnings yield vs 10-yr
-5.57pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-0.7%
EBITDA margin
-0.8%
ROE
-4.9%
ROIC
-5.5%
Revenue growth
54.0%

Insider activity, last 90 days

Net open-market
$-3.15m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Total revenues increased 56% to $743.2 million for the three months ended June 30, 2026, and 59% to $1,492.4 million for the six months ended June 30, 2026, compared to the respective prior-year periods, driven primarily by growth in our Medicare Advantage membership and higher per-member premium. Adjusted SG&A as a percentage of total revenues improved to 16% for the six months ended June 30, 2026, from 18% in the prior-year period, as revenue growth outpaced growth in our administrative cost base. Consolidated gross profit increased approximately 50% to $312.5 million for the six months ended June 30, 2026, broadly in line with our membership growth. …CLOVER HEALTH INVESTMENTS, CORP. /DE, 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →